 |
|
Mycophenolate Mofetil Is Effective in the Treatment of Atopic Dermatitis
Marcella Grundmann-Kollmann, MD;
Maurizio Podda, MD;
Falk Ochsendorf, MD;
Wolf-Henning Boehncke, MD;
Roland Kaufmann, MD;
Thomas M. Zollner, MD
Arch Dermatol. 2001;137:870-873.
ABSTRACT
| |
Objective To evaluate whether mycophenolate mofetil, a new immunosuppressive agent, is effective for treating moderate-severe atopic dermatitis (AD).
Design In an open-label pilot study, mycophenolate mofetil, 1 g, was given orally twice daily for 4 weeks. At week 5, the dosage was reduced to 500 mg twice daily until study end (week 8). Patients were followed up for 20 weeks.
Setting University hospital dermatology department.
Patients Ten consecutive patients with moderate-severe AD nonresponsive to standard therapy.
Main Outcome Measure Severity of AD as measured using the subjective SCORAD [SCORing Atopic Dermatitis] index.
Results Clinical efficacy was measured every 2 weeks using the subjective SCORAD index. Treatment with mycophenolate notably reduced the severity of AD within 4 weeks in all patients (P<.05), and after 8 weeks the mean ± SD SCORAD index dropped from the pretreatment value of 49.2 ± 13.8 to 21.9 ± 26.5 (P<.01). One patient had to discontinue mycophenolate therapy after 4 weeks because of the development of herpes retinitis. Except for this event, mycophenolate was tolerated well in all patients. Six of 7 patients who had responded to mycophenolate monotherapy had no relapse of disease during 20-week follow-up. In the 7 patients who finished the study, the SCORAD index was reduced by 74%, from 44.0 ± 7.8 before treatment to 11.4 ± 5.9 at 20-week follow-up.
Conclusions Mycophenolate is a highly effective drug for treating moderate-severe AD, with no serious adverse effects occurring in any patients. Thus, mycophenolate might develop into a promising alternative in the therapy of moderate-severe AD.
INTRODUCTION
ALTHOUGH ATOPIC dermatitis (AD) is a common inflammatory skin disease, there are no entirely satisfactory treatments. Potent glucocorticoids, although frequently effective, cannot be used continuously because of significant adverse effects. Newer modalities, such as oral cyclosporine, are likewise effective but often are limited by severe unwanted effects.1-2
Mycophenolate mofetil is a new entry into the field of immunosuppressive agents. Mycophenolate is the 2-morpholinoethyl ester of mycophenolic acid and is rapidly absorbed after oral administration. Mycophenolate is then hydrolyzed to its active metabolite mycophenolic acid, which is supposed to potently, selectively, and reversibly inhibit inosine monophosphate dehydrogenase and therefore suppress the de novo pathway of purine synthesis in T and B cells. Unlike most other cells, lymphocytes rely on the de novo pathway more than the salvage pathway for purine biosynthesis. Because mycophenolic acid specifically inhibits the de novo pathway, lymphocytes are the primary target of mycophenolic acid action in vivo, thus minimizing unwanted effects on other cell types.
Mycophenolic acid also exerts its immunomodulatory effects through inhibiting the leukocyte recruitment and glycosylation of lymphocytic glycoproteins involved in their adhesion to endothelial cells. Recently it has been shown that mycophenolate has an inhibitory effect on endothelial prostaglandin E2 production, which might lower the benefits of the prostaglandin E2–triggered immune response after organ transplantation.3-6
Mycophenolate has been approved for treating acute renal graft rejection and has been used to treat vasculitis, blistering autoimmune diseases, and pyoderma gangrenosum. To date, only limited data with mycophenolate in the treatment of AD are available.7-9 This study extends our previous limited experience with mycophenolate in AD to an additional 10 patients.
PATIENTS AND METHODS
Ten patients with moderate-severe AD (mean SCORAD [SCORing Atopic Dermatitis] index, 49.2; range, 38-80) who had not responded to conventional topical treatment or to systemic treatment with oral glucocorticoids, phototherapy, or cyclosporine were included in the 8-week study after giving oral informed consent (Table 1). Atopic dermatitis was diagnosed according to the criteria of Hanifin and Rajika.10 A 2-week washout period of systemically applied immunosuppressive agents was required before starting therapy with mycophenolate. Severity of AD was measured using the subjective SCORAD index at treatment weeks 0, 2, 4, 6, and 8 and at follow-up week 20. The subjective SCORAD index was developed in 1993 by the European Task Force on Atopic Dermatitis to create a standardized assessment method for AD11 and was modified in 1997.12 The subjective scoring index combines the extent (rule of 9) and severity of 5 intensity items (erythema, edema and papulation, oozing and crusts, excoriations, and lichenifications) and the subjective symptoms (daytime pruritus and sleep loss).11 All patients were given 1 g of mycophenolate mofetil orally twice daily during weeks 1 to 4; during weeks 5 to 8 the dosage was reduced to 500 mg twice daily. During the first 2 weeks, treatment with topical glucocorticoids was permitted; beginning with week 3, only emollient ointment was permitted.
|
|
|
|
Characteristics of 10 Patients With Atopic Dermatitis Undergoing Mycophenolate Mofetil Therapy*
|
|
|
Mycophenolate therapy was discontinued after 8 weeks, at which time each patient was followed up for 20 weeks. During follow-up, use of class 2 to 3 topical glucocorticoids was permitted if necessary.
All data satisfied the normality test and were analyzed using 1-way analysis of variance with the Tukey multiple comparison test using statistical software (InStat version 3.00 for Windows 95; GraphPad Software, San Diego, Calif). Data are given as mean ± SD; P<.05 is considered statistically significant.
RESULTS
Ten patients with moderate-severe AD were included in the study (initial subjective SCORAD index, 49.2 ± 13.8). These patients did not respond to conventional topical treatment or to systemic treatment with oral glucocorticoids, phototherapy, or cyclosporine. Treatment with mycophenolate significantly reduced the severity of AD within 4 weeks in all patients (SCORAD index, 27.5 ± 11.7; range, 16-53; P<.05) (Figure 1). After 4 weeks, 7 of 10 patients had cleared completely. Two patients primarily responded well to mycophenolate therapy, but after 5 to 6 weeks of treatment we observed a relapse of AD, although mycophenolate therapy was continued. One patient had to stop mycophenolate therapy after 4 weeks because of the development of herpes retinitis. Six of the 7 responders had lasting remission during 20-week follow-up (for a clinical example see Figure 2), and only 1 patient experienced a partial relapse, with an increase in the SCORAD index from 12 (at week 8) to 24 (at week 20). Nevertheless, in the 7 patients who completed the study, the SCORAD index at week 20 (11.4 ± 5.9; range, 6-24) was reduced by 74% compared with the initial index (44.0 ± 7.8; range, 38-60) (P<.001) (Figure 1).
|
|
|
|
Figure 1. Significant reduction in the SCORAD [SCORing Atopic Dermatitis] index in response to mycophenolate mofetil therapy.
|
|
|
|
|
|
|
Figure 2. Patient 6 before (A) and after (B) mycophenolate mofetil therapy.
|
|
|
Overall, mycophenolate therapy was well tolerated in all but 1 patient, who experienced herpes retinitis at week 4. Routine laboratory tests, including blood cell counts, liver and renal function tests, and electrolyte levels, were performed before the study and at biweekly intervals. Test results remained unremarkable throughout the study in all patients. In particular, leukopenia, anemia, and changes in liver function were not observed.
COMMENT
The results of this pilot study demonstrate that mycophenolate is highly effective in the treatment of moderate-severe AD. Because of the effectiveness of mycophenolate therapy in patients who relapsed while receiving conventional treatment with systemic glucocorticoids or cyclosporine, one may conclude that mycophenolate might be superior for treating moderate-severe AD. Adverse effects observed in patients undergoing transplantation treated with mycophenolate include gastrointestinal tract symptoms, leukopenia, and anemia. The actual risk of an increased incidence of viral and bacterial infection due to treatment with mycophenolate has been a matter of controversial discussion.12 Recent studies of mycophenolate therapy for blistering autoimmune diseases do not report an increase in the incidence of infections, as has been reported for patients receiving a transplant.7, 13 However, patients in the transplant studies were receiving other immunosuppressive agents concomitantly.13 One of our patients had to discontinue mycophenolate therapy because he developed herpes retinitis, which resolved quickly after treatment with acyclovir. Although there is no direct evidence of mycophenolate being a major cause of herpes retinitis, in this patient it seems likely that this might be due to immunosuppression resulting from mycophenolate therapy. However, to our knowledge, it has not been reported until now that mycophenolate monotherapy is associated with a significant increased risk of bacterial or viral infection such as herpes infection. Therefore, we have no evidence that regular antiviral therapy is necessary before starting mycophenolate therapy. In addition, it has been shown that mycophenolate strongly potentiates the antiherpes activity of acyclovir, ganciclovir, and penciclovir in vitro and in vivo,14-15 suggesting that it is sufficient to start antiviral therapy when clinical signs of herpes infection occur.
The results of this pilot study in 10 patients demonstrate that the adverse effects of mycophenolate therapy are acceptable, with no serious adverse effects occurring in any patients. In addition to being a highly effective drug in the treatment of moderate-severe AD, mycophenolate is also characterized by a low toxicity profile, causing only moderate adverse effects. Compared with the unwanted adverse effects of systemic glucocorticoid, azathioprine, or cyclosporine use, mycophenolate seems to have an improved risk-benefit ratio. In 6 of 10 patients, lasting remission for 20 weeks was observed. After the end of mycophenolate monotherapy (week 8), patients were allowed to use class 2 to 3 topical glucocorticoids in localized areas if necessary. This was considered a significant improvement by patients and dermatologists because before mycophenolate therapy, AD in all patients had been resistant to potent topical glucocorticoid and systemic immunosuppressive treatment (Table 1). Thus, mycophenolate might develop into a promising alternative for treating AD.
These promising initial results warrant initiation of controlled clinical trials comparing the safety and effectiveness of mycophenolate with that of conventional immunosuppressive agents. Because of the long-lasting remission in responders to mycophenolate therapy, intermittent mycophenolate modalities should be evaluated.
AUTHOR INFORMATION
Accepted for publication February 8, 2001.
Part of this work was supported by Hoffmann-La Roche, Grenzach-Whylen, Germany; Paul und Ursula Klein-Stiftung; and August Scheidel-Stiftung.
Corresponding author: Marcella Grundmann-Kollmann, MD, Department of Dermatology, Johann Wolfgang Goethe-University, Theodor-Stern-Kai 7, 60590 Frankfurt/Main, Germany.
From the Department of Dermatology, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany.
REFERENCES
| |
1. Larsen FS. Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol. 1993;28:719-713.
WEB OF SCIENCE
| PUBMED
2. Salek MS, Finlay AY, Luscombe DK, et al. Cyclosporin greatly improves quality of life of adults with severe atopic dermatitis: a randomized, double blind, placebo controlled trial. Br J Dermatol. 1993;129:422-430.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
3. Morris RE, Wang J, Blum JR, et al. Immunosuppressive effects of the morpholinoethylester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc. 1991;23:19-25.
WEB OF SCIENCE
| PUBMED
4. Lipsky JJ. Mycophenolate mofetil. Lancet. 1996;348:1357-1359.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
5. Blaheta RA, Leckel K, Wittig B, et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc. 1999;31:1250-1252.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
6. Blaheta RA, Nelson K, Opermann E, et al. Mycophenolate mofetil decreases endothelial prostaglandin E2 in response to allogenic T cells or cytokines. Transplantation. 2000;69:1977-1981.
PUBMED
7. Enk AH, Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol. 1999;135:54-56.
FREE FULL TEXT
8. Nousari CH, Lynch W, Anhalt GJ. The effectivness of mycophenolate mofetil in refractory pyoderma gangrenosum. Arch Dermatol. 1998;134:1509-1511.
FREE FULL TEXT
9. Grundmann-Kollmann M, Korting HC, Behrens S, et al. Successful treatment of severe refractory atopic dermatitis with mycophenolate mofetil. Br J Dermatol. 1999;141:175-177.
WEB OF SCIENCE
| PUBMED
10. Hanifin JM, Rajika G. Diagnostik features of atopic dermatitis. Acta Derm Venereol (Stockh). 1980;92(suppl):S44-S47.
11. Oranje AP, Stalder JF, Taieb A, et al for the ETAC Study Group. Scoring of atopic dermatitis by SCORAD using a training atlas by investigators from different disciplines. Pediatr Allergy Immunol. 1997;8:28-34.
WEB OF SCIENCE
| PUBMED
12. Kunz B, Oranje AP, Labreze L, et al. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology. 1997;195:10-19.
13. Siverman Kitchin JE, Keltz Pomerantz M, Pak G, et al. Rediscovering mycophenolic acid: a review of its mechanism, side effects, and potential uses. J Am Acad Dermatol. 1997;37:445-449.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
14. Neyts J, Andrei G, De Clerq E. The novel immunosuppressive agent mycophenolate mofetil markedly potentiates the antiherpesvirus activities of acyclovir, ganciclovir, and penciclovir in vitro and in vivo. Antimicrob Agents Chemother. 1998;42:216-222.
FREE FULL TEXT
15. Neyts J, De Clerq E. Mycophenolate mofetil strongly potentiates the anti-herpesvirus activity of acyclovir. Antiviral Res. 1998;40:53-56.
FULL TEXT
|
WEB OF SCIENCE
| PUBMED
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Archives of Dermatology Reader's Choice: Continuing Medical Education
Arch Dermatol. 2001;137(7):986-987.
FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Immunosuppressive Therapy Does Not Prevent the Occurrence of Immunoglobulin E-Mediated Allergies in Children and Adolescents With Organ Transplants
Dehlink et al.
Pediatrics 2006;118:e764-e770.
ABSTRACT
| FULL TEXT
Atopic and non-atopic eczema
Brown and Reynolds
BMJ 2006;332:584-588.
FULL TEXT
Mycophenolate mofetil and skin diseases
Hartmann and Enk
Lupus 2005;14:s58-s63.
ABSTRACT
Mycophenolate mofetil and skin diseases
Hartmann and Enk
Lupus 2005;14:s58-s63.
ABSTRACT
Treatment of Linear IgA Bullous Dermatosis of Childhood With Mycophenolate Mofetil
Farley-Li and Mancini
Arch Dermatol 2003;139:1121-1124.
FULL TEXT
Mycophenolate for Atopic Dermatitis, Too
Journal Watch Dermatology 2001;2001:5-5.
FULL TEXT
|
